RxDoctor Payments Data

Julie Seifert

Family · Irwin, PANPI 1982029435

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 39 payments — averaging $29.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$627
  • AstraZeneca$142
  • Pfizer$118
  • AbbVie$62
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$57
  • Viatris Specialty LLC$37
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$1,11697%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,148 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,582
Medicare patients
79
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$39,484
MounjaroTirzepatide26$30,531
EliquisApixaban26$19,827
TrulicityDulaglutide11$14,325
MyrbetriqMirabegron21$11,930
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,350
Breo ElliptaFluticasone/Vilanterol20$7,738
Albuterol Sulfate HfaAlbuterol Sulfate59$1,713
Atorvastatin Calcium162$1,494
Metoprolol Succinate116$1,386
Gabapentin75$1,355
Levothyroxine Sodium115$870
Fluticasone Propionate87$764
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide24$742
Duloxetine Hcl51$729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$17$44,85637 claims
Novo NordiskOzempic$627$39,48429 claims
PfizerEliquis$118$19,82726 claims
Astellas Pharma US IncMyrbetriq$21$11,93021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Irwin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →